This Project Grant award of $2,216,525.00 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) is funding a randomized controlled, double-blind, multicenter clinical trial at Cedars-Sinai Medical Center to determine the effects of pre-implantation, intrarenal artery injection of C1 esterase inhibitor (C1INH) on improving kidney transplant outcomes for recipients of deceased donor organs.
The trial aims to assess the impact of C1INH therapy on enhancing allograft function, reducing biopsy-proven acute rejection (BPAR), and improving other key outcomes over 12 months post-transplant. Associated mechanistic studies using biopsy and blood samples will provide insights into the intervention's effects. The work is expected to be completed over 7 years, with primary endpoint results available within 4-5 years.
The grant includes sub-awards to the University of Kansas Medical Center Research Institute, Northwestern University, and the University of Manitoba to support specific trial activities such as patient enrollment, sample collection, and laboratory testing. If successful, the researchers believe this novel therapeutic strategy could transform the field of kidney transplantation.
Generated 3/4/25, 6:16 AM